268 related articles for article (PubMed ID: 32571890)
1. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
Ngoi NY; Sundararajan V; Tan DS
Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890
[TBL] [Abstract][Full Text] [Related]
2. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer.
Gupta N; Huang TT; Horibata S; Lee JM
Pharmacol Res; 2022 Apr; 178():106162. PubMed ID: 35259479
[TBL] [Abstract][Full Text] [Related]
4. Targeting the replication stress response through synthetic lethal strategies in cancer medicine.
Ngoi NYL; Pham MM; Tan DSP; Yap TA
Trends Cancer; 2021 Oct; 7(10):930-957. PubMed ID: 34215565
[TBL] [Abstract][Full Text] [Related]
5. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
[TBL] [Abstract][Full Text] [Related]
6. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
7. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
[TBL] [Abstract][Full Text] [Related]
9. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
Gralewska P; Gajek A; Marczak A; Rogalska A
J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
[TBL] [Abstract][Full Text] [Related]
10. Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer.
Tang Q; Wang X; Wang H; Zhong L; Zou D
Cancer Biol Med; 2024 Feb; 20(12):915-21. PubMed ID: 38318945
[No Abstract] [Full Text] [Related]
11. Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.
Nikkilä J; Kumar R; Campbell J; Brandsma I; Pemberton HN; Wallberg F; Nagy K; Scheer I; Vertessy BG; Serebrenik AA; Monni V; Harris RS; Pettitt SJ; Ashworth A; Lord CJ
Br J Cancer; 2017 Jun; 117(1):113-123. PubMed ID: 28535155
[TBL] [Abstract][Full Text] [Related]
12. Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.
Huehls AM; Wagner JM; Huntoon CJ; Karnitz LM
Mol Pharmacol; 2012 Oct; 82(4):767-76. PubMed ID: 22833573
[TBL] [Abstract][Full Text] [Related]
13. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer.
Yang SH; Kuo TC; Wu H; Guo JC; Hsu C; Hsu CH; Tien YW; Yeh KH; Cheng AL; Kuo SH
World J Gastroenterol; 2016 Aug; 22(32):7275-88. PubMed ID: 27621574
[TBL] [Abstract][Full Text] [Related]
14. Targeting the replication stress response in cancer.
Forment JV; O'Connor MJ
Pharmacol Ther; 2018 Aug; 188():155-167. PubMed ID: 29580942
[TBL] [Abstract][Full Text] [Related]
15. Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress.
Liu S; Opiyo SO; Manthey K; Glanzer JG; Ashley AK; Amerin C; Troksa K; Shrivastav M; Nickoloff JA; Oakley GG
Nucleic Acids Res; 2012 Nov; 40(21):10780-94. PubMed ID: 22977173
[TBL] [Abstract][Full Text] [Related]
16. WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance.
Zheng H; Shao F; Martin S; Xu X; Deng CX
Sci Rep; 2017 Mar; 7():43517. PubMed ID: 28262781
[TBL] [Abstract][Full Text] [Related]
17. ATR/CHK1 inhibitors and cancer therapy.
Qiu Z; Oleinick NL; Zhang J
Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
[TBL] [Abstract][Full Text] [Related]
18. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
Li S; Wang L; Wang Y; Zhang C; Hong Z; Han Z
J Hematol Oncol; 2022 Oct; 15(1):147. PubMed ID: 36253861
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
20. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.
Peasland A; Wang LZ; Rowling E; Kyle S; Chen T; Hopkins A; Cliby WA; Sarkaria J; Beale G; Edmondson RJ; Curtin NJ
Br J Cancer; 2011 Jul; 105(3):372-81. PubMed ID: 21730979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
